Pancreatic adenocarcinoma: Treating a systemic disease with systemic therapy

Journal of the National Cancer Institute

Volumn 106, Issue 3, 2014, Pages

  Sohal, Davendra P S ^a   Walsh, R Matthew ^a   Ramanathan, Ramesh K ^b   Khorana, Alok A ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ALTERNATIVE HYPOTHESIS; AUTOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); EARLY CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENOMICS; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; MASTECTOMY; MOUSE MODEL; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC DISEASE; SYSTEMIC THERAPY; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANIMAL; EXPERIMENTAL NEOPLASM; MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR RECURRENCE; UNITED STATES;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; UNITED STATES;

EID: 84898731031     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju011     Document Type: Review

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Matrisian L, Aizenberg R, Rosenzweig A. The alarming rise of pancreatic cancer deaths in the United States. http://www.pancan.org/section-research/ reports/incidence-report.php. Accessed January 28, 2014.
3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-1703. doi:10.1056/NEJMoa1304369.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
5. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28(10):1645-1651.
6. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513-5518.
7. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(23):3778-3785.
8. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966.
9. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the US: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110(6):1227-1234.
10. Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19(1):169-175.
11. Boeck S, Ankerst DP, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis. Oncology. 2007;72(5-6):314-321.
12. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199-210; discussion 1210-1211.
13. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473-1481.
14. Gnerlich JL, Luka SR, Deshpande AD, et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg. 2012;147(8):753-760.
15. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806-1813.
16. Hishinuma S, Ogata Y, Tomikawa M, et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10(4):511-518.
17. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210.
18. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246(5):734-740.
19. Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/ GERCOR phase II study. J Clin Oncol. 2010;28(29):4450-4456.
20. Hammel P, Huguet F, Laethem J-LV, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol. 2013;31(15). Abstract LBA4003.
21. Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644-1662.
22. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/ neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.
23. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467(7319):1109-1113.
24. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114-1117.
25. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1-2):349-361.
26. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307(1):26-36.
27. Kabashima A, Higuchi H, Takaishi H, et al. Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer. 2009;124(12):2771-2779.
28. Roy LD, Sahraei M, Subramani DB, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011;30(12):1449-1459.
29. Halsted WS. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46(1):1-19.
30. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of vater. Ann Surg. 1935;102(4):763-779.
31. Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer. 1999;35(14):1963-1973.
32. Fisher B. Laboratory and clinical research in breast cancer - a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980;40(11):3863-3874.
33. Fisher ER, Fisher B. Experimental studies of factors influencing hepatic metastases. I. The effect of number of tumor cells injected and time of growth. Cancer. 1959;12(5):926-968.
34. Fisher B. Biological research in the evolution of cancer surgery: a personal perspective. Cancer Res. 2008;68(24):10007-10020.
35. Mukherjee S. The Emperor of All Maladies. New York: Scribner; 2010.
36. Rabinovitch R, Kavanagh B. Double Helix of breast cancer therapy: intertwining the Halsted and Fisher hypotheses. J Clin Oncol. 2009;27(15):2422-2423.
37. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol. 1994;12(10):2229-2234.
38. Fisher B, Anderson SJ. The breast cancer alternative hypothesis: is there evidence to justify replacing it? J Clin Oncol. 2010;28(3):366-374.
39. Fisher B, Wolmark N. Conservative surgery: the American experience. Semin Oncol. 1986;13(4):425-433.
40. Kimple RJ, Russo S, Monjazeb A, et al. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther. 2012;12(4):469-480.
41. MacKenzie S, Zeh H, McCahill LE, et al. A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC). J Clin Oncol. 2013;31(15s). Abstract 4038.
42. National Institutes of Health. ClinicalTrials.gov. http://clinicaltrials. gov/ ct2/results?term=%28folfirinox+OR+nab-paclitaxel%29+AND+pancr eatic+AND+%28preoperative+OR+neoadjuvant%29&Search=Search. Accessed January 28, 2014.